Golimumab for the treatment of ulcerative colitis
The introduction of therapeutic antibodies against tumor necrosis factor (TNF) had a major impact on the treatment of ulcerative colitis (UC). Infliximab and adalimumab are powerful agents that are used for remission induction and maintenance therapy in UC and have an acceptable safety profile. Howe...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958527/ |